Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults

Reuters

05-28

Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults

NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2538491466"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538491466\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538491466?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538491466","market":"us","top_or_hot":-1,"title":"Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-28 04:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL2yzZbT:1","article_id":"2538491466","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538491466","pubTimestamp":1748376346,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cumberland Pharmaceuticals Unveils Study Confirming Caldolor as Safe and Effective Opioid-Sparing Pain Management for Older Adults. NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc.  has announced the publication of a new clinical study assessing Caldolor  in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CPIX":"坎伯兰药业","BK4557":"大麻股"},"translate_title":"Cumberland Pharmaceuticals公布的研究证实Caldolor®可安全有效地治疗老年人阿片类药物疼痛","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPIX":0.9},"content_text":"Cumberland Pharmaceuticals Unveils Study Confirming Caldolor® as Safe and Effective Opioid-Sparing Pain Management for Older Adults\n    \n\n        NASHVILLE, Tenn., May 27, 2025/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) has announced the publication of a new clinical study assessing Caldolor® (intravenous ibuprofen) in patients aged 60 and older. The research, aimed at evaluating the drug's safety and efficacy, demonstrated a 23% reduction in morphine use, suggesting a potential opioid-sparing role for Caldolor in pain management among older adults. The study's findings highlight Caldolor's favorable safety profile and its applicability across a broad age range, from infants to older adults. This development marks a significant advancement in addressing the pain management needs of the aging population. Further outreach to healthcare providers is planned to communicate these findings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL96698) on May 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}